The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet.
Preclinical and clinical studies demonstrate that the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) as a triacylglycerol (TAG) or an ethyl ester are protective against cardiovascular disease. Both have significant TAG-lowering effects. We developed a concentrated ethyl ester of DHA (MATK-90, 900 mg/g) using microalgae as its source. This study evaluated the effects that different doses of MATK-90 had on lipid levels and clinical parameters in male Wistar rats fed a high-fructose diet used to induce hypertriglyceridemia (TAG > or = 300 mg/dL). Effects of MATK-90 were compared to those produced by a pharmaceutical product (Lovaza, formerly Omacor, P-OM3; 465 mg EPA + 375 mg DHA), a TAG oil used in food (DHASCO, algal-DHA, 40% DHA by weight), and a control (corn oil). Doses of MATK-90 (0.6, 1.3, 2.5, 5.0 g kg(-1) day(-1)), algal-DHA (2 g DHA kg(-1) day(-1)), and P-OM3 (5.0 g kg(-1) day(-1)) were administered by oral gavage for 28 days. A significant dose-related decrease was observed in TAG and cholesterol levels in all but the lowest dose of MATK-90 treatment group vs. control. The high-dose group of MATK-90 and the P-OM3 group produced similar reductions in TAG levels.
Ryan
Alan S
AS
Martek Biosciences Corporation, 6480 Dobbin Road, Columbia, MD 21045, USA. alryan@martek.com
Bailey-Hall
Eileen
E
Nelson
Edward B
EB
Salem
Norman
N
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D004032:Diet; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D004338:Drug Combinations; D004435:Eating / Q000187:drug effects; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D056890:Eukaryota; D005227:Fatty Acids / Q000378:metabolism; D005632:Fructose; D015228:Hypertriglyceridemia / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000378:metabolism
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004338:Drug Combinations; D005227:Fatty Acids; D000960:Hypolipidemic Agents; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D005632:Fructose; D002784:Cholesterol; D015118:Eicosapentaenoic Acid; C405603:Omacor